Stocks · Health care · Pharmaceutical Preparations

Q32 Bio Inc.

FIXX Clue Score74
United States Fiscal year ends December CIK 0001661998
13.81
+1.02%
Close, 9 Oct 2026 · USD

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close
13.81 on 9 Oct 2026
16 13 11 Aug 2026 Sep 2026 Oct 2026 19 Aug 2026 $14.15 20 Aug 2026 $13.82 21 Aug 2026 $13.52 24 Aug 2026 $12.74 25 Aug 2026 $12.02 26 Aug 2026 $12.89 27 Aug 2026 $12.73 28 Aug 2026 $11.27 31 Aug 2026 $11.68 1 Sep 2026 $11.78 2 Sep 2026 $11.88 3 Sep 2026 $12.17 4 Sep 2026 $12.65 8 Sep 2026 $13.19 9 Sep 2026 $12.65 10 Sep 2026 $12.25 11 Sep 2026 $13.72 14 Sep 2026 $12.03 15 Sep 2026 $11.87 16 Sep 2026 $12.10 17 Sep 2026 $11.90 18 Sep 2026 $13.04 21 Sep 2026 $12.68 22 Sep 2026 $12.54 23 Sep 2026 $12.57 24 Sep 2026 $12.87 25 Sep 2026 $13.02 28 Sep 2026 $13.04 29 Sep 2026 $13.18 30 Sep 2026 $13.08 1 Oct 2026 $13.48 2 Oct 2026 $14.22 5 Oct 2026 $13.92 6 Oct 2026 $15.67 7 Oct 2026 $14.21 8 Oct 2026 $13.67 9 Oct 2026 $13.81 Violette Shelia M. Chief Scientific Officer Sold at will $46.33K 25 Aug 2026 · at $16.56 · 2.1% of stake Kalowski Lee CFO and President Sold at will $65.78K 25 Aug 2026 · at $16.56 · 2.8% of stake Morrison Jodie Pope CEO Sold at will $163.03K 25 Aug 2026 · at $16.56 · 2.8% of stake
0 buys3 sales at will0 planned sales

Key numbers

Fiscal year 2025, ended 31 Dec 2025, as filed
Revenue
$53.74M
Net income
$29.82M
Free cash flow
$33.54M
Operating margin
31.5%
Net margin
55.5%
Return on equity
71.0%
Return on capital
40.2%
Revenue growth, 5 yr
81.9% a year

Revenue and net income

Fiscal years, as filed with the SEC · point at a year for the detail
3M -129M FY20 Fiscal year 2020 Revenue $2.70M Net income $128.69M Margin -4,762.9% 34M -96M FY21 Fiscal year 2021 Revenue $33.97M Net income $95.76M Margin -281.9% · growth +1,157.3% 3M -5M FY22 Fiscal year 2022 Revenue $3.21M Net income $5.01M Margin -156.0% · growth -90.6% 1M -54M FY23 Fiscal year 2023 Revenue $1.16M Net income $53.74M Margin -4,649.0% · growth -64.0% 0K -48M FY24 Fiscal year 2024 Revenue $0.00 Net income $47.73M Margin n/a · growth -100.0% 54M 30M FY25 Fiscal year 2025 Revenue $53.74M Net income $29.82M Margin 55.5%
RevenueNet incomeLoss

Latest insider transactions

From Form 4, most recent first
All of them →
DateInsiderTypeValueOf own stake
25 Aug 2026 Morrison Jodie Pope
CEO
Sold at will $163.03K 2.8%
25 Aug 2026 Kalowski Lee
CFO and President
Sold at will $65.78K 2.8%
25 Aug 2026 Violette Shelia M.
Chief Scientific Officer
Sold at will $46.33K 2.1%
28 May 2026 Xu Diyong
Director
Bought $15.00M 115%
28 May 2026 ORBIMED ADVISORS LLC
Director
Bought $15.00M 115%
25 Feb 2026 Morrison Jodie Pope
CEO
Sold at will $44.67K 10.0%